Zoonovac-V Vaccine

Zoonovac-V is administered intramuscularly following a prescribed immunization schedule, which may include pre-exposure prophylaxis for high-risk groups or post-exposure prophylaxis in conjunction with wound care and rabies immunoglobulin when indicated. The vaccine is produced using modern cell culture techniques ensuring high purity and safety. Common adverse effects are generally mild and transient, including localized pain, redness, and swelling at the injection site, with occasional systemic reactions such as fever or headache.

Contraindications include hypersensitivity to any component of the vaccine. Careful adherence to dosing schedules and guidelines is essential for optimal immunogenicity and protection. Zoonovac-V Vaccine is a critical component in rabies prevention strategies, contributing significantly to reducing morbidity and mortality associated with this invariably fatal disease.